Capacities of somatostatin analogues to treat castration-resistant prostate cancer

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Rusakov I.G.

Gorodskaia klinicheskaia bol'nitsa #57 Departamenta zdravookhraneniia Moskvy

Gritskevich A.A.

Vishnevsky Institute of Surgery Ministry of Health of the Russian Federation, Moscow, Russia

Capacities of somatostatin analogues to treat castration-resistant prostate cancer

Authors:

Rusakov I.G., Gritskevich A.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(1): 73‑76

Read: 638 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rusakov IG, Gritskevich AA. Capacities of somatostatin analogues to treat castration-resistant prostate cancer. P.A. Herzen Journal of Oncology. 2012;1(1):73‑76. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper considers the state-of-the-art of treatment for castration-refractory prostate cancer with prolonged-action octreotide and dexamethasone during hormonal deprivation. It also gives the data of meta-analyses of foreign and Russian studies of the efficacy and safety of octreotide depot used in this pathology.

Keywords:

castration-refractory prostate cancer

octreotide depot

somatostatin analogues

Authors:

Rusakov I.G.

Gorodskaia klinicheskaia bol'nitsa #57 Departamenta zdravookhraneniia Moskvy

Gritskevich A.A.

Vishnevsky Institute of Surgery Ministry of Health of the Russian Federation, Moscow, Russia

Close metadata

References:

Garin A.M. Dotsetaksel (Taksoter) v praktike lecheniya zlokachestvennykh opukholei. M.: Izd-vo "Klever Print"; 2003: 88-94.
Davydov M.I., Aksel' E.M. Zlokachestvennye novoobrazovaniya v Rossii i stranakh SNG v 2001g. M.; 2003: 7-10; 100-2.
Dudnichenko A.S. Sovremennye napravleniya gormonoterapii pri rake predstatel'noi zhelezy. Onkologiya. 2001; 3(2): 110-2.
Matveev B.P., red. Klinicheskaya onkourologiya. M.: Verdane; 2003: 435-601.
Matveev B.P., Bukharkin B.V., Kalinin S.A. Lechenie gormonorezistentnogo raka predstatel'noi zhelezy. V kn.: Materialy konferentsii "Onkologicheskaya urologiya: ot nauchnykh issledovanii k klinicheskoi praktike (sovremennye vozmozhnosti lecheniya opukholei predstatel'noi zhelezy, mochevogo puzyrya i pochki)". 2004: 28-31.
Chissov V.I., Starinskii V.V., Petrova G.V., red. Zlokachestvennye novoobrazovaniya v Rossii v 2009 g. M.; 2011.
Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. Eur. Urol. 2003; suppl.2: 1-2.
Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005; 16(3): 481-8.
Crawford E.D., Rosenblum M., Ziada A.M., Lange P.H. Hormone-refractory prostate cancer. Urology. 1999; 54(6A, suppl.): 1-7.
Di Silverio F., Sciarra A. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer. J. Urol. 2003; 170(5):1812-6.
Dimopoulos M.A., Kiamouris C., Gika D. et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology. 2004; 63(1):120-5.
Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med. 1993; 118: 804-18.
Jemal A., Siegel R., Ward E., Hao Y., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58(2): 71-96.
Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer. Cancer Care. 2001; 8(6): 487-95.
Koutsilieris M., Mitsiades C.S., Bogdanos J. et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin. Cancer Res. 2004; 10(13): 4398-405.
Mitsiades C.S., Bogdanos J., Karamanolakis D. et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res. 2006; 26(5B): 3693-700.
Mitsiades C.S., Mitsiades N.S., McMullan C.J. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004; 5(3): 221-30.
Mitsiades N., Schultz N., Taylor B.S., Hieronymus H., Satagopan N., Scardino J.R. et al.; Prostate Sanseg Genome Project Group. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate sanseg: Targets for nowel personalized therapies. J. Clin. Oncol. 2009; 27(suppl.):15s: abstr.5002.
Montgomery R.V., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.R., Higano C.S. et al. Maintenance of intratumoral androgens in metastatic prostate canser: a mechanism for castration-tesistant tumor growth. Sanseg Res. 2008; 68(11): 4447-54.
Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur. J. Cancer. 2001; 37(suppl. 8): S4-66.
Pollak M.N., Schally A.V. Mechanism of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med. 1998; 217: 143-52.
Quinn M., Babb P. Patterns and trends in prostate cancer incedence, survival, prevalence and mortality. Part 1: international comparisons. Br. J. Urol. Int. 2002; 90(2): 162-73.
Saltz L., Trochanowski B., Buckley M. et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72: 244-8.
Scher H.I., Steineck G., Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995; 46: 142-8.
Stanbrough M., Bubleu G.J., Ross K., Golub T.R., Rubin M.A., Penning T. M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate sanseg. Sanseg Res. 2006; 66(5): 2815-25.
Vainas I.G. Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy. 2001; 47: 109-26.

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.